You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care.
Of the 28 companies in the index, 12 firms saw their stock prices increase, while 16 firms' share prices decreased.
Natera previously filed infringement lawsuits against ArcherDx around four other patents related to cell-free DNA detection in oncology.
The firm generated $46.2 million in revenues compared to $53.5 million in the prior year, which was better than analysts' estimate of $39.6 million.
Four diagnostic firms have gone public so far this year, with three of the companies based in China but filing for US initial public offerings.
Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased.
By combining with ArcherDX, Invitae will gain tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response.
The San Francisco-based firm reported $64.2 million in revenues, up from $40.6 million a year ago and beating the average Wall Street estimate of $59.4 million.
The available data suggests PGx may be useful in managing medications for COVID-19 patients and in helping people struggling with the mental health impact of the pandemic.
Invitae will provide free genetic testing on a 53-gene panel and counseling to patients suspected of having an LSD to facilitate earlier diagnosis and appropriate treatment.